Search
Confirm
Close

ABOUT Viwit

With high-quality products and services, we continue to create more value for our customers, employees, shareholders and society, and contribute our talents and efforts to a healthier and better life

COMPANY PROFILE

    Viwit is an innovation driven biopharmaceutical and healthcare company with integrated research and development, production and marketing systems. Viwit is committed to building a platform for pharmaceutical innovation and commercialization, and establishing an ecosystem that serves the healthcare needs of the general public.

    Viwit was founded in 2006 as an R&D lab. With the collaborative efforts of the Viwit team, Viwit Pharmaceutical has evolved from developing chiral borane products to making drug intermediates, active pharmaceutical ingredients and biopharmaceutical products. Viwit has two integrated product research and development (R&D) centers, three cGMP production facilities (refer to history of Viwit), and marketing distribution systems in China, the United States, Canada, European Union and other regions. Viwit is continuously focusing and expanding its business scope and operations in the biopharmaceutical and healthcare industry.

PRODUCT INTRODUCTION

We are committed to developing into a global leading medical and health enterprise based on the overall competitive advantage of the industrial chain and based on technological innovation


HIGH DEMAND PRODUCTS

Adhering to customer demand, building core competitiveness, and striving to provide better and higher quality health products and services

Title

Levofloxacin Hydrochloride Injection 5ml: 0.5g

【Drug Name】 <br/>
&emsp;Generic Name: Levofloxacin Hydrochloride Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.5g<br/>
Title

Levofloxacin hydrochloride Injection 5ml: 0.3g

【Drug Name】 <br/>
&emsp;Generic Name: Levofloxacin Hydrochloride Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.3g<br/>
Title

Puerarin Injection 5ml: 0.25g

【Drug Name】 <br/>
&emsp;Generic Name: Puerarin Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.25g<br/>
Title

Puerarin Injection 8ml: 0.4g

【Drug Name】 <br/>
&emsp;Generic Name: Puerarin Injection<br/>
【Strength】 <br/>
&emsp;8ml: 0.4g<br/>

INNOVATION 

& collaboration platform 

CDMO

Viwit platform provides CDMO services of APIs and intermediates, oral solids (tablets, capsules), sterile liquid products (small volume injections-ampoules, vials, eye drops). 

威智医药

Project Collaboration

Viwit platform provides R&D project cooperation and commercialization, covering the entire pharma industrial value chain from finished drugs to APIs.              

威智医药
威智医药

Joint Venture

Provide marketing, fund raising and other resources.

In-/Out-Licensing

Viwit is dedicated to developing and providing innovative, valuable drugs to the general public and assisting our business partners to bring high-quality products to global markets.

威智医药

NEWS CENTER

Make due contribution to the development of the industry and society, and strive to become the pacesetter and pioneer of the industry.

2023

12 -07

On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.

2023

10 -31

On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.

2023

10 -30

Congratulations to Viwit Pharmaceuticals that Viwit obtained the Drug Production License C for solid preparations and injections on July 28th, 2023. Meaning, that Viwit’s production lines for solid preparations and injections own the qualification on contracted manufacturing.

2023

10 -18

Viwit’s sterile blow-fill-seal (BFS) eye drops manufacturing facility is established in 2021. The BFS production line fulfills the need for an advanced aseptic manufacturing process using the state of the art Rommelag 434 BFS system. Pharmaceutical grade low-density polyethylene (PE) is used to ensure product quality and prevent leachable and leakage. A strip of 15 doses attached to each other can be created and filled within a few seconds. Every single BFS ampule is detected for leakage to ensure the integrity of the dose.

2023

09 -18

Viwit Pharmaceuticals will be participating in CPHI Barcelona 2023 in Oct. 24th~26th, 2023 at Fira Barcelona Gran Via, Spain. Welcome to visit our booth 7D30 or contact us to learn more about our full portfolio of products, services, and solutions. We look forward to seeing you soon!